← boardnext 2026-09
EWTX
Edgewise Therapeutics, Inc.distress 4/10 · elevated risk$37.73-2%today-22% from 52w high
Nephrology 1
Lead: Becker Muscular Dystrophy · target Cardiac myosin
Revenue
pre-revenue
Liquidity
$33M
Runway
0.2 yrs
Shares 1y
+2%
Price & events
+26.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
-1.2%
1W
-2.8%
1M
+20.8%
3M
+31.9%
6M
+162.2%
1Y
+73.2%
2Y
+87.5%
5Y
+25.8%
All
Overview
- Market Cap
- $4.06B
- Volume
- 40.70K
- 52 Week Range
- $12.68 – $48.35
- Total Shares
- 107.59M
- Float Shares
- 67.12M
- Short %
- 13.80%
- % Held by Insiders
- 0.45%
- % Held by Institutions
- 113.89%
- RVOL
- 0.03x
- Beta
- 0.28
Pipeline stages · 3 programs
Sevasemten
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
EDG-7500Cardiac myosin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
[14C]-EDG-7500Cardiac myosin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 11 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mg | Becker Muscular Dystrophy | — | active not recruiting |
| 2027-01 Estimated 50% readout ~2027-02-15 | Phase 2 | Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3 | Duchenne Muscular Dystrophy | — | active not recruiting |
| 2027-03 Estimated 50% readout ~2027-04-15 | Phase 2 | Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3 | Duchenne Muscular Dystrophy | — | active not recruiting |
| 2031-02 Estimated 50% readout ~2031-03-18 | Phase 2 | Sevasemten | Becker Muscular Dystrophy | — | enrolling by invitation |
| 2026-06 | Phase 1 | EDG-7500 | Healthy Adult Participants | 24 | not yet recruiting |
Show all 11 trials · 6 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06 | Phase 2 | EDG-7500 | Hypertrophic Cardiomyopathy | 100 | active not recruiting |
| 2026-05 | Phase 1 | EDG-15400 | Healthy Adults | 108 | recruiting |
| 2026-05 | Phase 1 | EDG-7500 | Hepatic Impairment (HI) | 32 | recruiting |
| 2025-12-22 | Phase 1 | EDG-7500 | Renal Impairments | 37 | completed |
| 2025-02-22 | Phase 1 | sevasemten, Verapamil | Healthy Subjects | 42 | completed |
| 2025-01-17 | Phase 1 | [14C]-EDG-7500 | Healthy Volunteer | 8 | completed |
Catalyst news & presentations · 8
- 2026Guided 40%trial initiationsecondaryPhase 3sevasemten · Initiate pivotal Phase 3 study for Duchenne.SEC 8-K
- fourth quarter of 2026Guided 70%readoutPhase 2sevasemten · Report GRAND CANYON resultsSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026trial initiationsecondaryPhase 3EDG-7500 · Initiate Phase 3 CIRRUS-HCM trialSEC 8-K
- first half of 2026readoutPhase 2novel heart failure candidate · Report data from Phase 2 clinical trial of heart failure candidateSEC 8-K
- second half of 2025trial initiationsecondaryPhase 3sevasemten · Initiate Phase 3 LYNX and FOX trialsSEC 8-K
- second half of 2025readoutPhase 2EDG-7500 · Report initial readout of 12-week data from Part D Phase 2 CIRRUS-HCM trialSEC 8-K
- first half of 2025regulatory submissionFiled (NDA/BLA)novel heart failure candidate · File IND for novel heart failure candidateSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $50 (+32% upside) · 13 analysts
- 2026-07-20Evercore ISI GroupOutperform
- 2026-07-09OppenheimerOutperform
- 2026-07-06GuggenheimBuy
- 2026-06-17RBC CapitalOutperform
- 2026-06-17Goldman SachsNeutral
- 2026-06-16HC Wainwright & Co.Buy
Competitors — Cardiac myosin
- CYTKCYTOKINETICS INC$10.1B · D7
Recent news
- 2026-07-21Edgewise Therapeutics (EWTX) Trades At A Rich P B, Is The Premium Justified? - Yahoo Finance
- 2026-07-21EWTX Maintained by Evercore ISI Group -- Price Target Raised to $55 - GuruFocus
- 2026-07-20Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $55 - Moomoo
- 2026-07-20EWTX Maintained by Evercore ISI Group -- Price Target Raised to $55 - GuruFocus
- 2026-07-20EWTX Maintained by Evercore ISI Group -- Price Target Raised to $55 - GuruFocus
- 2026-07-18(EWTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
- 2026-07-18Form 4 Edgewise Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
- 2026-07-17Edgewise Therapeutics director gets 16,377 options | EWTX Insider Trading - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.